|
ACADEMIC
Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia
 |
Author(s) |
(a)Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T
(b) Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C |
 |
Title(s) |
(a)Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection
(b) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study |
|
Reference(s) |
(a) Circulation 1999;99:1540–7 (b) Circulation 2000;102:1755–60 |
|
Disease |
Coronary artery disease
|
|
Purpose |
To determine whether C. pneumoniae infection is an additional risk factor for atherosclerosis in patients with coronary artery disease
|
|
Study design |
Randomised, double-blind, placebo-controlled
|
|
Follow-up |
2 years
|
|
Patients |
302 patients (150 azithromycin, 152 placebo), aged 30-88 years, with previous MI or CABG, percuataneous cornonary intervention or > 50% stenosis on angiography of at least one major coronary artery, and who had a seropositive reaction to C. pneumoniae
|
|
Treatment regimen |
Azithromycin, 500 mg/day for 3 days then 500 mg/week for 3 months, or placebo
|
|
Results |
22 patients in the azithromycin group and 25 patients in the placebo group experienced ≥ 1 primary cardiovascular event (9 cardiovascular deaths, 1 resuscitated cardiac arrest, 11 MI, 3 stroke, 4 unstable angina pectoris, 19 unplanned coronary revascularisation). There was no significant difference in the two groups |
|
|
|
